[HTML][HTML] Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I Donovan-Banfield, R Penrice-Randal… - Nature …, 2022 - nature.com
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
R Penrice-Randal, H Goldswain… - Nature …, 2022 - search.ebscohost.com
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
R Penrice-Randal, H Goldswain… - Nature …, 2022 - eprints.soton.ac.uk
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
R Penrice-Randal, H Goldswain… - Nature …, 2022 - archive.lstmed.ac.uk
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
R Penrice-Randal, H Goldswain… - Nature …, 2022 - econpapers.repec.org
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
I Donovan-Banfield, R Penrice-Randal… - Nature …, 2022 - europepmc.org
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
R Penrice-Randal, H Goldswain… - Nature …, 2022 - ui.adsabs.harvard.edu
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
I Donovan-Banfield, R Penrice-Randal, H Goldswain… - 2022 - cabidigitallibrary.org
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
R Penrice-Randal, H Goldswain… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
[HTML][HTML] Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
R Penrice-Randal, H Goldswain… - Nature …, 2022 - ncbi.nlm.nih.gov
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …